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Abstract
Critical illness polyneuropathy/critical illness myopathy (CIP/CIM)
is a major cause of mortality and long-term morbidity in critically ill
patients, but the true incidence and prevalence of these
syndromes are not known. Hermans and colleagues show that
when intensive insulin therapy is used as part of routine clinical
practice in the intensive care unit, the incidence of CIP/CIM as
determined by electrophysiologic testing is reduced. Our under-
standing of the mechanisms responsible for inducing prolonged
weakness in intensive care unit patients is limited, and the role of
hyperglycemia in modulating these processes is unknown.
Intensive insulin therapy currently remains the only effective
therapeutic intervention that has been shown to reduce the
incidence of CIP/CIM.
In a recent issue of Critical Care, Hermans and colleagues
showed that intensive insulin therapy (IIT) significantly
reduces the incidence of electrophysiologic detection of
neuromuscular complications in critically ill patients [1].
These findings are consistent with data obtained from two
randomized controlled trials using IIT [2,3], which showed
that IIT decreases the incidence of critical illness poly-
neuropathy/critical illness myopathy (CIP/CIM) diagnosed by
electroneuromyography as well as reducing the duration of
mechanical ventilation and shortening the length of stay in the
intensive care unit (ICU). Improvements in electrophysiology
presumably translate into improvements in respiratory muscle
strength, decreasing the duration of mechanical ventilation
and the length of ICU stay – although none of these studies
objectively measured muscle strength.
It is important to note that our understanding of the mecha-
nisms that lead to CIP/CIM is substantially limited. Abundant
data suggest that sepsis induces a myopathy characterized
by reductions in muscle force-generating capacity (force
generation per cross-sectional area), loss of muscle mass
and altered bioenergetics, but the mechanisms by which
acute hyperglycemia induces prolonged or sustained
alterations in the peripheral nervous system and in skeletal
muscle are largely unknown.
How does glucose damage tissues? Glucose toxicity has
been explained by increased cellular glucose flux and
mitochondrially generated oxidative stress. For example,
Nishikawa and colleagues showed that excessive mito-
chondrial superoxide generation is responsible for hyper-
glycemia-induced damage in endothelial cells [4]. Vincent
and colleagues showed recently that 2 hours of high glucose
exposure results in severe oxidative stress, mitochondrial
disruption, activation of caspase 3 and apoptosis in cultured
neurons [5]. Glucose overload and subsequent oxidative
stress, therefore, may account for damage to neuronal tissue
during acute hyperglycemia. This mechanism cannot account
for acute hyperglycemia-induced changes in skeletal muscle,
however, because glucose uptake in skeletal muscle is insulin
dependent whereas glucose flux in neurons is insulin
independent. In fact, if the skeletal muscle glucose uptake
was sufficient, hyperglycemia would not occur. As such, it is
reasonable to postulate that the mechanisms of hyper-
glycemia-induced muscle dysfunction are likely to be different
from those that mediate hyperglycemia-induced neuronal injury.
What is the evidence that hyperglycemia produces derange-
ments in skeletal muscle that result in weakness? It is critical
to understand that overall muscle strength depends on
muscle-specific force generation (that is, force generation per
muscle mass or force per cross-sectional area) and on total
muscle mass. These two parameters represent distinct
aspects of muscle function, and the processes that modulate
Commentary
Hyperglycemia and acquired weakness in critically ill patients:
potential mechanisms
Leigh Ann Callahan and Gerald S Supinski
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Kentucky, L543 Kentucky Clinic, 740 South
Limestone, Lexington, KY40536, USA
Correspondence: Leigh Ann Callahan, lacall2@email.uky.edu
See related research by Hermans et al., http://ccforum.com/content/13/1/R5
Published: 26 March 2009 Critical Care 2009, 13:125 (doi:10.1186/cc7728)
This article is online at http://ccforum.com/content/13/2/125
© 2009 BioMed Central Ltd
CIP/CIM = critical illness polyneuropathy/critical illness myopathy; ICU = intensive care unit; IIT = intensive insulin therapy.Critical Care    Vol 13 No 2 Callahan and Supinski
Page 2 of 2
(page number not for citation purposes)
force generation and muscle mass are different. In this
context, only a few studies have examined the effects of more
prolonged hyperglycemia on skeletal muscle contractile
function, with some showing reductions in muscle-specific
force generation whereas others show no change [6,7]. It is
therefore unclear whether hyperglycemia alters muscle force
generation. On the other hand, Du and colleagues have
shown that hyperglycemia results in skeletal muscle caspase 3
activation, degradation of myofibrillar proteins (specifically
actin), and subsequent activation of the ubiquitin–
proteasomal degradation pathway, leading to muscle atrophy
[8]. Similarly, Russell and colleagues recently demonstrated
in cultured myotubes that high glucose induces protein loss
via activation of caspase 3, oxidative stress, and decreased
protein synthesis [9]. These data indicate that hyperglycemia
activates pathways involved in muscle atrophy. In addition,
studies evaluating hyperglycemia-induced mitochondrial
alterations in skeletal muscle reveal inconsistent data – with
some showing normal function, while other studies show
decrements in oxidative phosphorylation [10,11]. Moreover,
data suggest that mitochondrial ultrastructure, complex
activity, and muscle protein content are preserved in patients
treated with IIT [12].
These data raise several interesting questions. Does acute
hyperglycemia alter neurons and skeletal muscle in such a
way as to produce sustained weakness in patients who
survive critical illness? Cheung and colleagues show that
many acute respiratory distress syndrome survivors have
persistent functional impairment with decreased exercise
tolerance, muscle weakness and muscle wasting up to
2 years after ICU discharge [13]. Over the past decade, the
concept of metabolic memory has described the pheno-
menon that hyperglycemia produces ongoing sustained
damage in target tissues even after blood glucose levels are
normalized [14]. Is it possible that acute hyperglycemia
induces metabolic memory in neurons and/or in skeletal
muscle and produces the prolonged weakness we see in our
patients? It is conceivable that hyperglycemia-induced
mitochondrial free radical generation, irreversible modification
of mitochondrial proteins and mitochondrial DNA damage
[14] might induce ongoing injury in neurons and skeletal
muscle. Such processes could also inhibit repair. If this is
true, perhaps CIP/CIM develops because of an acquired
mitochondrial myopathy. While entirely speculative, such
possibilities should be entertained.
In summary, substantial evidence supports that IIT reduces
the incidence of CIP/CIM. The proposed mechanisms by
which insulin therapy protects neurons and skeletal muscle
are related to its anabolic effects and anti-inflammatory
effects. While IIT remains the only intervention shown to
reduce the occurrence of CIP/CIM, many patients develop
prolonged weakness even with IIT, indicating that other
processes are involved. Future studies to elucidate the
mechanisms responsible for CIP/CIM should also address
the role of hyperglycemia in these processes. Importantly, if
ongoing trials reveal that IIT imparts a prohibitive risk in ICU
patients, then this information is crucial.
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